Loading...
NPI 1932102951 · Hattiesburg, MS · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jaime Jimenez Agosto is a ophthalmology physician provider located in Hattiesburg, Mississippi. This profile covers 36 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jaime Jimenez Agosto |
| Address | 1420 S 28th Ave |
| City | Hattiesburg |
| State | MS |
| ZIP | 39402 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | May 23, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.7M |
| Medicaid | $4K |
This provider’s billing is effectively Medicare-driven: lifetime Medicare revenue is $3.7M versus just $4K in Medicaid, so commercial/Medicare programs almost entirely underpin the practice’s revenue stream and Medicaid activity is de minimis in scale. Analysts should treat this profile as a Medicare-centric operation when assessing network impact or utilization risk.
Medicare revenue is highly concentrated in intravitreal drug administration: the top three Medicare codes (J2777, J0178, J0179) account for 75.3% of the provider’s Medicare revenue. Those codes are all high-cost ophthalmic injections (faricimab, aflibercept, and brolucizumab), indicating the practice’s financial engine is medical-retina therapeutics rather than primary eye care or routine procedures.
J2777 (faricimab) is the single largest Medicare revenue driver at $1.6M and 56.4K claims, and the provider ranks #78 of 2039 nationally (96th percentile), meaning this clinician is a notably above-typical national volume participant for faricimab administrations. By contrast J0178 (aflibercept) yields $880.7K and sits at the 69th percentile (#996 of 3204), which is more typical, while J0179 (brolucizumab) is relatively concentrated but high-ranked (#4 of 64, 95th percentile), showing selective leadership in certain newer or less-widely used agents.
The practice also reports very high procedural and diagnostic throughput consistent with a retina specialty clinic: 92134 (retinal imaging/OCT) shows 2.2K claims and ranks in the 97th percentile nationally, and procedural codes such as 67028 and 67036 appear with nontrivial volume and high national percentiles. Together with the injection mix, this code pattern supports a service line oriented to medical retina management plus capacity for posterior-segment procedures.
Office visit E/M billing for Medicare is an important secondary revenue stream and also a statistical standout: 99213 (1.1K claims, $66.1K revenue) ranks in the 99th percentile and is labeled an "extreme outlier," while 99212 likewise ranks at the 100th percentile. These extreme-outlier rankings suggest substantially higher office-visit volume per clinician than is typical nationally, consistent with frequent follow-up visits inherent to intravitreal treatment regimens.
Surgical retina capacity is evident but more modest in revenue share: multiple vitrectomy and retina repair codes (e.g., 67036, 67041, 67042, 67113) are present with smaller revenue contributions individually, yet several rank well above typical national volume (for example 67036 is in the 82th/93th percentile range depending on the metric shown), indicating the provider performs a mix of office-based medical retina and periodic operative procedures.
On the Medicaid side the provider’s billing is extremely concentrated and low-revenue: the top three Medicaid codes account for 91.1% of the provider’s Medicaid revenue, led by 99213, 67028, and 99214. However, because total Medicaid revenue is only $4K, these code-level shares represent negligible financial impact and modest to below-average in-state competitive standing (e.g., 99213 ranks #1303 of 1909 in-state).
Tenure and operational stability are long-standing: the NPI was enumerated on 2005-05-23 (~21 years ago), which combined with the concentrated Medicare injection volume suggests an experienced retina-focused clinician with an established referral and treatment workflow for intravitreal therapies.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
36 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 56,400 | $30 | $1.6M |
| J0178 | Injection, aflibercept, 1 mg | 1,300 | $680 | $880.7K |
| J0179 | Injection, brolucizumab-dbll, 1 mg | 1,040 | $250 | $257.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,530 | $90 | $142.2K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 570 | $220 | $123.2K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 950 | $120 | $111.5K |
| J3490 | Unclassified drugs | 70 | $1,400 | $93.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,120 | $60 | $66.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,180 | $30 | $58.9K |
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram | 360 | $160 | $58K |
Showing 1–10 of 36
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
36 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 6 | 20 | 670 | $680 | $990.1K |
| J2777 | 1 | 10 | 8,460 | $30 | $325.2K |
| J0179 | 1 | 10 | 1,040 | $250 | $257.5K |
| J2781 | 2 | 10 | 950 | $120 | $141.8K |
| 67028 | 8 | 30 | 600 | $80 | $107K |
| Q5128 | 1 | 10 | 440 | $220 | $87.3K |
| J7351 | 2 | 10 | 360 | $160 | $76.6K |
| 67041 | 3 | 10 | 20 | $1,090 | $35.9K |
| 92242 | 2 | 10 | 180 | $170 | $30.5K |
| J7312 | 3 | 10 | 200 | $150 | $30.3K |
Showing 1–10 of 36
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 250 | $10 | $1.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 230 | $10 | $1.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 60 | $10 | $680 |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 350 | $1 | $350 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,303 | 1,910 | 930 | $60 | $278.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,387 | 1,670 | 720 | $50 | $196.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 9 | 20 | 300 | $30 | $88.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 13 | 40 | 70 | $10 | $19.3K |
Other providers in the same ZIP code as Jaime Jimenez Agosto, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.